Abstract. In order to reverse the malignant characteristics of hypopharyngeal cancer, the proteasome inhibitor MG132 was introduced into FaDu/T cells and the mechanisms underlying its effects were investigated. The multi-drug resistance (MDR) sensitivities of FaDu/T and FaDu/T-MG132 cancer cells to several chemotherapeutics were investigated by a 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) assay. Apoptosis was measured by staining cells with Annexin V and propidium iodide (PI) double staining. Reverse transcription-polymerase chain reaction and western blot analysis were conducted to detect mRNA and corresponding protein levels of the MDR-and apoptosis-related genes P-glycoprotein (P-gp), caspase-3, Bcl-2 and Bax. The nuclear protein of nuclear factor κ-light-chain-enhancer of activated B cells. (NF-κB) and p53 were also investigated via western blot analysis. Compared with FaDu/T cells, the drug resistance of FaDu/T + MG132 cells to cisplatin (DDP), 5-fluorouracil (5-FU), doxorubicin (Dox) and vincristine (VCR) decreased. With increased expression of caspase-3 and Bax and decreased expression of Bcl-2, the anti-apoptotic ability markedly decreased in FaDu/T + MG132 cells. P-gp and NF-κB significantly decreased; however, p53 increased in FaDu/T + MG132 cells. These results suggested that the proteasome inhibitor MG132 reversed the malignant characteristics of FaDu/T by enhancing apoptosis and inhibiting P-gp. MG132 was also able to inhibit the nuclear translocation of NF-κB and increase the expression of p53.
Introduction
Due to the concealed location of onset and a lack of clear symptoms in the early stages, the majority of hypopharyngeal carcinoma patients are in the advanced stage when diagnosed and this results in substantial morbidity and mortality (1) . The traditional treatment option for terminal hypopharyngeal carcinoma is surgical resection (2) . This strategy, however, has evolved from the point of view of pure treatment to maximize preservation of hypopharyngeal function, placing emphasis upon the quality of life of these patients. Consequently, the standard approach for the treatment of these patients is radiotherapy and chemotherapy (3) . Taxol or cisplatin (DDP) are used for treatment. However, chemoresistance and anti-apoptotic characteristics of cancer cells are a major obstacle for effective chemotherapy. A study has demonstrated that several molecules, including ATP-binding cassette (ABC) genes and anti-apoptotic-associated proteins have lead to the development of the multi-drug resistance (MDR) phenotype of cancer cells. The expression of ABC transporters and anti-apoptotic proteins result in an ATP-driven efflux of antitumor drugs from the interior of cancer cells and thereby led to decreased intracellular drug accumulation and failure to induce apoptosis (4) .
To reverse these malignant characteristics, a substantial amount of effort has been dedicated to developing novel drugs. In recent years, increased attention has been paid to the proteasome pathway, which is crucial in the regulation of the cell cycle, differentiation and apoptosis in a number of normal cellular processes (5) . Several studies have investigated the potential anticancer capacity of proteasome inhibitors in vitro and in vivo. As a strong proteasome inhibitor, MG132 has been verified to downregulate the MDR protein P-glycoprotein (P-gp) and anti-apoptotic protein Bcl-2 (6). Furthermore, it is also able to increase the expression of apoptosis-related proteins Bax and caspase-3 (7, 8) . This has warranted further investigation of MG132. However, at present, the mechanisms underlying the effect of MG132 remain largely unknown, particularly in head and neck squamous cell carcinoma (HNSCC). In the present study, , to the best of our knowledge, MG132 was introduced for the first time into the FaDu/T hypopharyngeal cancer cell line, established by exposing hypopharyngeal carcinoma FaDu cell lines to escalating concentrations of Taxol (FaDu/T) as demonstrated in our previous study (9) . In addition, the present study aimed to determine whether MG132 is able to further reverse malignant behavior, including MDR and anti-apoptotic characteristics. 
Materials and methods

Materials
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). The reverse transcription reaction was performed using the ExScript RT reagent kit (Takara Bio, Inc., Dalian, China) in a final volume of 20 µl containing 1 µg of total RNA, 4 µl of 5X ExScript buffer, 1 µl dNTP mixture, 1 µl Oligo(dT) primer, 0.5 µl ExScript RTase, 0.5 µl RNase inhibitor and RNase-free water to reach a volume of 20 µl. The reverse transcription reaction was performed at 42˚C for 15 min and the reaction was terminated by heating at 95˚C for 2 min. PCR was performed according to the manufacturer's instructions of Takara TaqTM under the following conditions: Pre-degeneration at 95˚C for 3 min, degeneration at 95˚C for 60 sec, renaturation at 58˚C for 45 sec and elongation at 72˚C for 60 sec, for a total of 25 cycles. All the experiments were conducted three times. The primers used were as follows: Forward: 5'-CTGCTCAAGTTAAAGGGGCTAT-3' and reverse: 5'-AACGGTTCGGAAGTTTTCTATT-3' for ABCB1/ P-gp; forward: 5'-GCTACGAGTGGGATACTGGAGA-3' and reverse: 5'-AGTCATCCACAGAGCGATGTT-3' for Bcl-2; forward: 5'-TCATCCAGGATCGAGCAGA-3' and reverse: 5'-AAAGTAGAAGAGGGCAACCAC-3' for Bax; forward: 5'-TTTGGAACGGACCTGT-3' and reverse: 5'-CACGGGATCTGTTTCTTTGC-3' for caspase-3; and forward: 5'-GTGGGGCGCCCCAGGCACCA-3' and reverse: 5'-CTCCTTAATGTCACGCACGATTT-3' for actin.
Western blot analysis. Total protein was extracted using radioimmune precipitation protein lysis buffer according to the Protein Extraction Technology Guide. Nuclear proteins were solubilized and then fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
The Bradford method was used to determine the protein concentration of the supernatant. The samples (40 µg of each total protein) were used for western blot analysis with the primary antibodies (P-gp, 1:400, mouse anti-human; Bcl-2, 1:400 mouse anti-human; Bax, 1:400, rabbit anti-human; caspase-3, 1:400, rabbit anti-human; actin, 1:2000, mouse antihuman; NF-κB, 1:200, rabbit anti-human; p53, 1:200, mouse anti-human and lamin A, 1:200 rabbit anti-human). The bands of P-gp, Bcl-2, Bax, caspase-3, NF-κB, p53, lamin A and actin were visualized at apparent molecular weights of 170, 26, 23, 32, 53, 76 and 43 kDa, respectively. The relative OD ratio was calculated from three experiments by comparison with actin with NIH software Image J (National Institutes of Health, Bethesda, MD, USA).
Flow cytometric analysis for cell apoptosis. For apoptosis assessment, Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) were used. Following trypsinization, cells were resuspended in binding buffer (20 µl) containing Annexin V-FITC (5 µl; 20 µg/ml) and PI (10 µl; 20 µg/ml) for at least 10 min at room temperature, and then binding buffer (300 µl) was added prior to analysis with system II, version 3.0 software (Beckman Coulter, Miami, FL, USA).
Statistical analysis. Data are presented as the mean ± standard error of the mean. Statistical calculations were performed using the SPSS 16.0 software package (SPSS Inc., Chicago, IL, USA). One-way analysis of variance was applied for analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
Establishment of the taxol-resistant cell line FaDu/T and cross-resistance profiles.
As reported in our previous study, FaDu/T cells were constructed and had MDR characteristics in Taxol, Dox, VCR, 5-FU and DDP (9 Fig. 1 ).
Protein levels of P-gp, Bcl-2, Bax and caspase-3 in FaDu/T and FaDu/T + MG132 cells.
The expression tendency of P-gp, Bcl-2, Bax and caspase-3 protein levels was the same as the gene levels. Image J software was used to analyze the relative photo density, using actin as the standard. Considering FaDu/T/actin as 100, the relative photo densities of the FaDu/T + MG132 groups were: P-gp/actin, 33.73±3.67; Bcl-2/actin, 16.19±0.13; caspase-3/actin, 464.01 ± 38.38 and Bax/actin, 712.99 ± 13.28, respectively. Statistical analysis demonstrated that there was a significant difference between FaDu/T and FaDu/T + MG132 cells (P<0.05; Fig. 2 ). 05; Fig. 3 ).
Different proportions of apoptotic cells between FaDu/T and FaDu/T + MG132 cells.
To assess the apoptotic induction capacity of MG132, FaDu/T cells were treated with MG132 for 24 h and the proportions of apoptotic cells were investigated. Compared with the apoptotic rate of FaDu/T cells (4.45±1.60%), the rate in cells exposed to MG132 was 32.9±2.39%. These results indicated that MG132 has a more potent apoptotic induction capacity in FaDu/T cells (Fig. 4) .
Discussion
Currently, the standard approach of advanced HNSCC treatment, particularly hypopharyngeal carcinoma, is surgery combined with radiotherapy and chemotherapy. In terms of chemotherapy, MDR of cancer cells has always been a major problem in treatment. To further investigate the MDR reversal of hypopharyngeal cancer cells, based on the established MDR hypopharyngeal carcinoma cell line FaDu/T, MG132 was introduced into FaDu/T cells and the internal mechanisms of the effects of MG132 were investigated.
Our previous study demonstrated that, compared with FaDu cells, the expression of the MDR protein P-gp and anti-apoptotic protein Bcl-2 markedly increased in FaDu/T cell lines, whereas the apoptosis-related proteins caspase-3 and Bax decreased. P-gp, encoded by the multi-drug resistance 1 (MDR1) gene, is an efflux transporter, which is important in the MDR of cancer cells and transports numerous substrates, including Taxol and VCR. As an anti-apoptotic member of the Bcl family, Bcl-2 inhibits the release of apoptotic molecules, including the caspase family members, by interacting with Bax (10). The increased expression of P-gp and Bcl-2 appears to be a critical factor of chemotherapy and apoptosis resistance in FaDu/T cells. In order to overcome the malignant behavior of FaDu/T tumor cells, numerous chemotherapeutic drugs have been demonstrated to be effective in vivo; however, the toxicity and side effects largely limit the clinical application over a long period. The results of previous in vitro trials indicate that the proteasome inhibitor MG132 is a potent P-gp inhibitor and apoptosis inducer in several types of tumor cells (11) . To verify whether MG132 has the ability to reverse the MDR and anti-apoptotic properties of FaDu/T cells, experiments were performed based on the previous study. With the addition of MG132 to FaDu/T cells, P-gp was markedly decreased, Bcl-2/Bax began to decrease and caspase-3 increased. The data from assays indicated that MG132 is able to markedly reverse the malignant behavior of FaDu/T cells. However, the molecular mechanisms underlying the effects of MG132 require further investigation.
As a promising proteasome inhibitor, MG132 is able to induce a range of antitumor activity, including the restoration of sensitivity to chemotherapy and provocation of apoptosis (12) . It has been reported that MG132 exerts these functions through inhibiting the degradation of IκB proteins and therefore suppresses the nuclear translocation and activation of NF-κB (13) . As an important transcription factor, the activation state of NF-κB positively regulates the expression of P-gp and Bcl-2 in cancer cells, as a binding site for NF-κB exists in the P-gp and Bcl-2 promoter region (14, 15) . Several studies have indicated that p53, a transcription factor, is able to induce the expression of the apoptotic factor Bax, which is also one of the most commonly mutated genes in HNSCC (16) . As the substrate of the proteasome, the degradation of p53 may also be inhibited by MG132 (17) . As the present study demonstrated, when MG132 was added to FaDu/T cells, the nuclear translocation of NF-κB and the degradation of p53 were all inhibited and consequently the expression of P-gp and Bcl-2 decreased. In addition, the expression of the apoptosis-related proteins Bax and caspase-3 was markedly upregulated when FaDu/T cells were treated with MG132. For caspase-3, certain studies have indicated that MG132 is able to cause mitochondrial dysfunction and subsequently cause cytochrome C release, which results in the activation of caspase-3 and caspase-dependent apoptotic processes (8) .
To further investigate the apoptotic state of FaDu/T cells affected by MG132, flow cytometry was conducted and it was revealed that MG132 is able to significantly increase the apoptotic ratio compared with FaDu/T cells. Additionally, in terms of MDR, the present study also revealed that the multi-drug resistance of FaDu/T cells to DDP, 5-FU, Dox and VCR was markedly decreased when treated with MG132. This involved the reduction of P-gp and Bcl-2 accompanied by the upregulation of Bax and caspase-3, and led to apoptosis of the majority of FaDu/T cells.
In conclusion, these observations indicated that the upregulation of Bax and caspase-3 were involved in MG132-induced apoptosis in the FaDu/T cancer cell line. In addition, decreased P-gp and Bcl-2 levels were observed in FaDu/T cancer cells treated with MG132. The mechanisms underlying the effects of MG132 are based on the NF-κB and p53 pathways. All the alterations in apoptosis and drug resistance relative genes are beneficial for MG132 to reverse MDR in FaDu/T cells. These results may be valuable for the prevention of MDR and anti-apoptosis derived from cancer cells in clinical cancer chemotherapy.
